Annual Total Debt
$1.27 M
-$2.82 M-68.85%
31 December 2023
Summary:
Brainstorm Cell Therapeutics annual total debt is currently $1.27 million, with the most recent change of -$2.82 million (-68.85%) on 31 December 2023. During the last 3 years, it has fallen by -$5.94 million (-82.33%). BCLI annual total debt is now -82.33% below its all-time high of $7.22 million, reached on 31 December 2020.BCLI Total Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Debt
$841.00 K
-$121.00 K-12.58%
30 September 2024
Summary:
Brainstorm Cell Therapeutics quarterly total debt is currently $841.00 thousand, with the most recent change of -$121.00 thousand (-12.58%) on 30 September 2024. Over the past year, it has dropped by -$2.05 million (-70.91%). BCLI quarterly total debt is now -88.35% below its all-time high of $7.22 million, reached on 31 December 2020.BCLI Quarterly Total Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCLI Total Debt Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -68.8% | -70.9% |
3 y3 years | -82.3% | -84.7% |
5 y5 years | +100.0% | -68.0% |
BCLI Total Debt High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -82.3% | at low | -84.9% | at low |
5 y | 5 years | -82.3% | -88.3% | at low | |
alltime | all time | -82.3% | -88.3% |
Brainstorm Cell Therapeutics Total Debt History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $841.00 K(-12.6%) |
June 2024 | - | $962.00 K(-14.2%) |
Mar 2024 | - | $1.12 M(-12.1%) |
Dec 2023 | $1.27 M(-68.8%) | $1.27 M(-55.9%) |
Sept 2023 | - | $2.89 M(-12.2%) |
June 2023 | - | $3.29 M(-10.5%) |
Mar 2023 | - | $3.68 M(-10.1%) |
Dec 2022 | $4.09 M(-19.4%) | $4.09 M(-6.5%) |
Sept 2022 | - | $4.38 M(-7.7%) |
June 2022 | - | $4.74 M(-14.7%) |
Mar 2022 | - | $5.56 M(+9.5%) |
Dec 2021 | $5.08 M(-29.6%) | $5.08 M(-7.7%) |
Sept 2021 | - | $5.50 M(-8.9%) |
June 2021 | - | $6.04 M(-6.7%) |
Mar 2021 | - | $6.48 M(-10.2%) |
Dec 2020 | $7.22 M(+205.0%) | $7.22 M(+381.1%) |
Sept 2020 | - | $1.50 M(-15.9%) |
June 2020 | - | $1.78 M(-11.6%) |
Mar 2020 | - | $2.02 M(-14.8%) |
Dec 2019 | $2.37 M(>+9900.0%) | $2.37 M(-10.0%) |
Sept 2019 | - | $2.63 M(-7.3%) |
June 2019 | - | $2.84 M(-6.8%) |
Mar 2019 | - | $3.04 M(>+9900.0%) |
Dec 2018 | $0.00(0.0%) | $0.00(0.0%) |
Sept 2018 | - | $0.00(0.0%) |
June 2018 | - | $0.00(0.0%) |
Mar 2018 | - | $0.00(0.0%) |
Dec 2017 | $0.00(0.0%) | $0.00(0.0%) |
Sept 2017 | - | $0.00(0.0%) |
June 2017 | - | $0.00(0.0%) |
Mar 2017 | - | $0.00(0.0%) |
Dec 2016 | $0.00(0.0%) | $0.00(0.0%) |
Sept 2016 | - | $0.00(0.0%) |
June 2016 | - | $0.00(0.0%) |
Mar 2016 | - | $0.00(0.0%) |
Dec 2015 | $0.00(0.0%) | $0.00(0.0%) |
Sept 2015 | - | $0.00(0.0%) |
June 2015 | - | $0.00(0.0%) |
Mar 2015 | - | $0.00(0.0%) |
Dec 2014 | $0.00(0.0%) | $0.00(0.0%) |
Sept 2014 | - | $0.00(0.0%) |
June 2014 | - | $0.00(0.0%) |
Mar 2014 | - | $0.00(0.0%) |
Dec 2013 | $0.00 | $0.00(0.0%) |
Sept 2013 | - | $0.00(0.0%) |
June 2013 | - | $0.00(0.0%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2013 | - | $0.00(0.0%) |
Dec 2012 | $0.00(0.0%) | $0.00(0.0%) |
Sept 2012 | - | $0.00(0.0%) |
June 2012 | - | $0.00(0.0%) |
Mar 2012 | - | $0.00(0.0%) |
Dec 2011 | $0.00(-100.0%) | $0.00(0.0%) |
Sept 2011 | - | $0.00(0.0%) |
June 2011 | - | $0.00(0.0%) |
Mar 2011 | - | $0.00(-100.0%) |
Dec 2010 | $137.00 K(-63.0%) | $137.00 K(+234.1%) |
Sept 2010 | - | $41.00 K(+4000.0%) |
June 2010 | - | $1000.00(-88.9%) |
Mar 2010 | - | $9000.00(-97.6%) |
Dec 2009 | $370.00 K(-16.5%) | $370.00 K(+40.2%) |
Sept 2009 | - | $264.00 K(+28.2%) |
June 2009 | - | $206.00 K(-50.0%) |
Mar 2009 | - | $412.00 K(-7.0%) |
Dec 2008 | $443.00 K(-71.3%) | $443.00 K(-3.9%) |
Sept 2008 | - | $461.00 K(+5.7%) |
June 2008 | - | $436.00 K(-68.5%) |
Mar 2008 | - | $1.39 M(-10.1%) |
Dec 2007 | $1.54 M(+36.9%) | $1.54 M(+0.8%) |
Sept 2007 | - | $1.53 M(-17.6%) |
June 2007 | - | $1.86 M(+21.3%) |
Mar 2007 | - | $1.53 M(+33.8%) |
Dec 2006 | $1.13 M(+127.1%) | - |
Sept 2006 | - | $1.14 M(+19.2%) |
June 2006 | - | $959.50 K(+93.5%) |
Mar 2006 | - | $495.90 K(>+9900.0%) |
Mar 2006 | $495.90 K(>+9900.0%) | - |
Dec 2005 | - | $0.00(0.0%) |
Sept 2005 | - | $0.00(0.0%) |
June 2005 | - | $0.00(0.0%) |
Mar 2005 | $0.00(0.0%) | $0.00(0.0%) |
Dec 2004 | - | $0.00(0.0%) |
Sept 2004 | - | $0.00(0.0%) |
June 2004 | - | $0.00(0.0%) |
Mar 2004 | $0.00(-100.0%) | $0.00(-100.0%) |
Dec 2003 | - | $31.00 K(0.0%) |
Sept 2003 | - | $31.00 K(+47.6%) |
June 2003 | - | $21.00 K(0.0%) |
Mar 2003 | $21.00 K(+107.9%) | $21.00 K(0.0%) |
Dec 2002 | - | $21.00 K(-34.8%) |
Sept 2002 | - | $32.20 K(-20.3%) |
June 2002 | - | $40.40 K |
Mar 2002 | $10.10 K | - |
FAQ
- What is Brainstorm Cell Therapeutics annual total debt?
- What is the all time high annual total debt for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual total debt year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly total debt?
- What is the all time high quarterly total debt for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly total debt year-on-year change?
What is Brainstorm Cell Therapeutics annual total debt?
The current annual total debt of BCLI is $1.27 M
What is the all time high annual total debt for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual total debt is $7.22 M
What is Brainstorm Cell Therapeutics annual total debt year-on-year change?
Over the past year, BCLI annual total debt has changed by -$2.82 M (-68.85%)
What is Brainstorm Cell Therapeutics quarterly total debt?
The current quarterly total debt of BCLI is $841.00 K
What is the all time high quarterly total debt for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly total debt is $7.22 M
What is Brainstorm Cell Therapeutics quarterly total debt year-on-year change?
Over the past year, BCLI quarterly total debt has changed by -$2.05 M (-70.91%)